Selasa, 1 April 2025 (14:04)
Selasa, 1 April 2025 (14:04)
 Music |
 Video |
 Movies |
 Chart |
 Show |
 | The Use of Novel PI3K Inhibitors in CLL (OncLive) View |
 | PI3K Inhibitors in R/R CLL (OncLive) View |
 | TGR-1202, novel PI3K delta inhibitor, for hematological malignancies (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
 | Role of PI3K inhibitors in clinical practice: Uses and pitfalls (HMP Education) View |
 | Update on PI3K inhibitors for CLL: Idelalisib, copanlisib, duvelisib, and umbralisib (HMP Education) View |
 | Role of PI3K-Targeted Therapy in CLL (OncLive) View |
 | PI3 Kinase Inhibitors in CLL (OncLive) View |
 | TGR-1202, a next generation PI3K-delta inhibitor in CLL and B-cell lymphomas (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
 | PI3 Kinase Inhibitors for Relapsed/Refractory CLL (OncLive) View |
 | Overcoming toxicities when combining PI3K inhibitors with other treatments (VJHemOnc – Video Journal of Hematology \u0026 HemOnc) View |
